User profiles for P. Quartier
Pierre QuartierNecker Verified email at aphp.fr Cited by 24214 |
Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers
…, A Insalaco, Y Uziel, D Rigante, P Quartier… - Annals of the …, 2015 - ard.bmj.com
The objective of this work was to develop and validate a set of clinical criteria for the
classification of patients affected by periodic fevers. Patients with inherited periodic fevers (familial …
classification of patients affected by periodic fevers. Patients with inherited periodic fevers (familial …
Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature
U Meinzer, P Quartier, JF Alexandra, V Hentgen… - Seminars in arthritis and …, 2011 - Elsevier
OBJECTIVES: Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory
disorder common in Mediterranean populations. FMF is associated with mutations of the …
disorder common in Mediterranean populations. FMF is associated with mutations of the …
[PDF][PDF] The emerging role of interleukin-1ß in autoinflammatory diseases
… Quartier has received speaking fees from Novartis Pharma (less than $10,000). Dr. So
has received consulting fees from Novartis Pharma and UCB (less than $10,000 each). …
has received consulting fees from Novartis Pharma and UCB (less than $10,000 each). …
[PDF][PDF] Cryopyrin-associated periodic syndromes
P Quartier, F Rodrigues, S Georgin-Lavialle - Rev Med Interne, 2018 - researchgate.net
… Pierre Quartier : investigateurs et coordonnateur d’essai clinique pour Novartis, consultant
pour Novartis et pour SOBI, séminaires pour Novartis et pour SOBI, invitation à des congrès …
pour Novartis et pour SOBI, séminaires pour Novartis et pour SOBI, invitation à des congrès …
[HTML][HTML] Use of canakinumab in the cryopyrin-associated periodic syndrome
…, KS Leslie, E Hachulla, P Quartier… - … England Journal of …, 2009 - Mass Medical Soc
… but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31
… in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events …
… in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events …
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial
… arthritis was 6 months for patients given placebo (insufficient events to calculate IQR);
insufficient events had occurred in the abatacept group for median time to flare to be assessed (p=…
insufficient events had occurred in the abatacept group for median time to flare to be assessed (p=…
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic …
P Quartier, F Allantaz, R Cimaz, P Pillet… - Annals of the …, 2011 - ard.bmj.com
… At M1, 8/12 responders were receiving anakinra and 1 responder receiving placebo (p=0.003).
Ten patients from the placebo group switched to anakinra; nine were responders at M2. …
Ten patients from the placebo group switched to anakinra; nine were responders at M2. …
[PDF][PDF] Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and …
J Feldmann, AM Prieur, P Quartier, P Berquin… - The American Journal of …, 2002 - cell.com
Chronic infantile neurological cutaneous and articular (CINCA) syndrome is a severe
chronic inflammatory disease of early onset, characterized by cutaneous symptoms, central-…
chronic inflammatory disease of early onset, characterized by cutaneous symptoms, central-…
[HTML][HTML] Canakinumab for the treatment of autoinflammatory recurrent fever syndromes
…, M Moutschen, P Quartier… - … England Journal of …, 2018 - Mass Medical Soc
… -resistant familial Mediterranean fever (P<0.001), 35% versus 6% of those with mevalonate
kinase deficiency (P=0.003), and 45% versus 8% of those with TRAPS (P=0.006). The …
kinase deficiency (P=0.003), and 45% versus 8% of those with TRAPS (P=0.006). The …
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
P Quartier, P Taupin, F Bourdeaut… - … : Official Journal of …, 2003 - Wiley Online Library
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset
type - Quartier - 2003 - Arthritis & … P values were determined by Fisher's exact test. …
type - Quartier - 2003 - Arthritis & … P values were determined by Fisher's exact test. …